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Background: No study to date has evaluated the efficacy and safety of everolimus with reduced-exposure
cyclosporine in Japanese de-novo renal transplant (RTx) patients.
Methods: This 12-month, multicenter, open-label study randomized (1:1) 122 Japanese de-novo RTx patients to
either an everolimus regimen (1.5 mg/day starting dose (target trough: 3 to 8 ng/ml) + reduced-dose cyclosporine)
or a mycophenolate mofetil (MMF) regimen (2 g/day + standard dose cyclosporine). All patients received
basiliximab and corticosteroids. Key endpoints at month 12 were composite efficacy failure (treated biopsy-proven
acute rejection, graft loss, death, or loss to follow-up) and renal function (estimated glomerular filtration rate;
Modification of Diet in Renal Disease-4).
Results: Clear cyclosporine exposure reduction was achieved in the everolimus group throughout the study (52%
reduction at month 12). Month 12 efficacy failure rates showed everolimus 1.5 mg to be non-inferior to MMF
(11.5% vs. 11.5%). The median estimated glomerular filtration rate at month 12 was 58.00 ml/minute/1.73 m2 in the
everolimus group versus 55.25 ml/minute/1.73 m2 in the MMF group (P = 0.063). Overall, the incidence of adverse
events was comparable between the groups with some differences in line with the known safety profile of the
treatments. The everolimus group had a higher incidence of wound healing events and edema, whereas a higher
rate of cytomegalovirus infections was reported in the MMF group.
Conclusions: This study confirmed the efficacy of everolimus 1.5 mg/day (target trough: 3 to 8 ng/ml) in Japanese
RTx patients for preventing acute rejection, while allowing for substantial cyclosporine sparing. Renal function and
safety findings were comparable with previous reports from other RTx populations.
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In Japan, the standard immunosuppressive therapy for
renal transplant (RTx) patients comprises a quadruple
regimen of basiliximab induction with a calcineurin in-
hibitor (CNI; cyclosporine A (cyclosporine) or tacroli-
mus), mycophenolate mofetil (MMF) and corticosteroids
[1]. This CNI-based regimen remains the mainstay of
immunosuppression following kidney transplantation
worldwide [2], but improvements in long-term graft sur-
vival are restricted by the chronic nephrotoxicity associ-
ated with CNI therapy [3,4]. Intense efforts are being
made to develop immunosuppressive strategies that per-
mit early CNI minimization or elimination, potentially
leading to a reduction in CNI-related nephrotoxicity and
other adverse events (AEs) without compromising acute
rejection rates.
Everolimus, a mammalian target of rapamycin
(mTOR) inhibitor with potent immunosuppressive
and antiproliferative effects [5], has shown good
efficacy and tolerability when used in combination
with a CNI in de novo kidney transplant recipients
[6-14]. However, coadministration of everolimus with
standard-exposure CNI therapy adversely affects renal
function due to potentiation of CNI-related nephro-
toxicity [7,9,15]. A number of studies have therefore
assessed a variety of everolimus-based, CNI-sparing
protocols in order to identify the optimal balance
between preventing rejection and preserving graft
function [10-14]. Results from large, randomized
controlled trials have demonstrated the effectiveness
of reduced-exposure cyclosporine with an initial
everolimus dose of 1.5 mg/day, subsequently adjusted
to target an everolimus trough concentration (C0) of 3
to 8 ng/ml [6,12-14]. The most recent of these trials
(A2309) confirmed that this regimen was non-inferior
in terms of the primary efficacy endpoint to standard-
exposure cyclosporine with mycophenolic acid based
on a total of 277 patients in each group [14].
These trials, however, were largely conducted in non-
Asian patients (87 to 92%). Moreover, a high proportion
of grafts were from deceased-donor recipients (45 to
100%), whereas in Japan virtually all solid organ trans-
plants are undertaken with living donors [6,12-14]. A
single study has demonstrated that the pharmacokinetics
of everolimus are similar in Japanese or non-Japanese
volunteers [16], as recommended by the Pharmaceuticals
and Medical Devices Agency of Japan [17]. However,
clinical trials of a reduced CNI regimen with an
everolimus target exposure of 3 to 8 ng/ml are lacking
in Japanese or other Asian populations.
The current randomized, multicenter, 12-month study
compared the efficacy and safety of de novo everolimus
with reduced-exposure cyclosporine to MMF with
standard-dose cyclosporine in Japanese RTx patients.Methods
Study design
This was a 12-month, multicenter, randomized, open-
label study in Japanese adult de novo RTx patients. The
study was conducted from February 2008 to August
2010. Following eligibility screening, patients were strati-
fied by donor type (deceased donor or living donor) and
randomized (1:1) when the graft function was confirmed
just after transplantation into either the everolimus group
(everolimus 1.5 mg (targeted C0: 3 to 8 ng/ml) + reduced-
dose cyclosporine) or the MMF group (MMF 2 g/day +
standard-dose cyclosporine) All patients received
basiliximab induction therapy + corticosteroids.
The randomization list was produced by an independent
clinical research organization using a validated system that
automated the random assignment of treatment arms to
randomization numbers.
The independent ethics committee at each center ap-
proved this study and written informed consent was
obtained from each patient before enrollment. The study
was conducted and monitored according to Good Clinical
Practice guidelines.
Patients
Patients aged 18 to 65 years undergoing primary kidney
transplantation were eligible. Key exclusion criteria in-
cluded no evidence of graft function within 24 hours of
transplantation, patients of kidneys with a cold ischemia
time >24 hours; donor age >65 years; patients of
multiorgan, ABO-incompatible, positive T-cell cross-match
or HLA identical living-related-donor transplants; or most
recent anti-HLA class I panel-reactive antibodies >20% by
complement-dependent cytotoxicity-based assay or >50%
by flow cytometry or ELISA.
Immunosuppression and other concomitant medications
The initial dose of the study medication was given within
24 hours (if difficult due to the patient’s condition, then
within 36 hours) post transplantation. From day 5
onwards, cyclosporine dose adjustments were made based
on C0 (determined by local laboratory). Target cyclospor-
ine C0 concentrations in the everolimus 1.5 mg group
started with 100 to 200 ng/ml and were lowered to 75 to
150 ng/ml starting at month 2, then 50 to 100 ng/ml
starting at month 4, and 25 to 50 ng/ml from month 6
onwards. In the MMF group, patients started with a cyclo-
sporine C0 target concentration of 200 to 300 ng/ml,
which was lowered to 100 to 250 ng/ml starting at month
2 with this target range to be maintained for the remain-
der of the study. Everolimus doses were adjusted from day
5 onwards to maintain a C0 targeted at 3 to 8 ng/ml (mea-
sured by the central laboratory). Therapeutic drug moni-
toring was mandatory throughout the duration of the
study. All patients received basiliximab (20 mg) within
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according to local practice. Corticosteroids were adminis-
tered according to local practice, at a minimum dose of
5 mg/day for 12 months. Cytomegalovirus (CMV)
prophylaxis (including pre-emptive therapy) was man-
datory for all cases in which the donor tested positive and
the recipient tested negative for CMV. The duration of
prophylaxis was not defined in the protocol. All cases
other than CMV-positive donors and CMV-negative re-
cipients were treated according to local practice. The drug
and dose of the therapy were not defined in the protocol
and were according to local practice of the study site.
CMV prophylaxis was also recommended following any
antibody treatment of acute rejection episodes.
Study endpoints
Efficacy
The primary endpoint was efficacy failure, defined as the
composite of treated biopsy-proven acute rejection
(BPAR), graft loss, death or loss to follow-up (LTFU) at
month 12; LTFU was defined as a patient who did not
experience treated BPAR, graft loss or death and whose
last day of contact was prior to the month 12 visit. The
main secondary endpoint was the composite of graft
loss, death or LTFU at month 12. In all suspected rejec-
tion episodes, a graft core biopsy (read by the local and
central pathologists according to the updated Banff ’97
criteria [18]) was performed within 48 hours. The
treated BPAR endpoint was assessed using the central
pathologists’ reading.
Safety
The main safety endpoint was renal function at month
12. Renal function was determined by estimated glom-
erular filtration rate (eGFR) using the Modification of
Diet in Renal Disease formula [19]. Other safety assess-
ments included reported AEs and serious AEs as well as
clinical laboratory measurements and vital signs.
Statistical analyses
The primary efficacy analyses were conducted on the
intent-to-treat population (all patients randomized). The
non-inferiority test was based on confidence intervals
(CIs) constructed using the Z-test statistic. One-sided
95% CIs and two-sided 90% CIs for the difference in pri-
mary efficacy failure rates at 12 months between the
everolimus and MMF arms were computed. Everolimus
was considered non-inferior to MMF if the upper limit
of the 95% CI was less than 13%. Kaplan–Meier survival
analyses were performed on the rates of composite effi-
cacy failure and its components. For each of the second-
ary efficacy endpoints, simple event rate estimates
(proportion of events) were compared for the everolimus
group with the MMF group using Z-statistics based onone-sided 95% CIs for differences in event rates. The
eGFR at 12 months was summarized using descriptive
statistics. The Wilcoxon rank-sum test was used to
compare the two groups. Except for the renal function
analyses, safety analyses were performed on the safety
population (patients who received at least one dose of
study drug and had a post baseline safety assessment).
Sample size calculation
The efficacy failure rates at month 12 for the everolimus
and MMF groups were assumed to be 19% and 20%, re-
spectively. Owing to the limited number of RTx patients
available, a maximum of 120 patients (60 patients/arm)
were expected to be enrolled. A sample size of 60
patients per arm had 61% power to show everolimus
was statistically non-inferior to MMF at one-sided 0.05
levels and non-inferiority margin 13%.
Results
Patient disposition
The study population included a total of 122 patients, ran-
domized 1:1 to the everolimus (n = 61) and MMF (n = 61)
groups (intent-to-treat population; safety population).
More than 90% of patients completed the study in both
treatment groups and more than 85% of patients com-
pleted the 12-month period on study medication. A total
of eight patients discontinued the study at month 12 and
all of the study discontinuations were due to withdrawal
of consent (Figure 1). Overall, demographic and baseline
characteristics were comparable between the groups and
are presented in Table 1. The mean age was 42.5 years for
the everolimus group and 38.6 years for the MMF group.
The majority of patients were male (75.4% of everolimus
patients and 60.7% of MMF patients). Donor characteris-
tics were generally similar for both groups. The mean age
of donors was 52.3 years for the everolimus group and
55.3 years for the MMF group. Except for one deceased
donor each in both the groups, all donors were living and
the majority of the donors were living related (59.0% in
the everolimus group and 70.5% in the MMF group).
Immunosuppressant dose and exposure
The majority of everolimus patients (>85% from day 7 on-
wards) were maintained within the targeted everolimus
exposure, with the mean everolimus C0 ranging from
3.4 to 5.5 ng/ml (Figure 2a). Although a higher propor-
tion of everolimus patients were above the cyclosporine
target range versus the MMF group, a clear separation
of cyclosporine exposure was achieved between the
everolimus group and the MMF group throughout the
study period with a 52% lower mean and median ex-
posure in the everolimus group at month 12 (median:
63.0 ng/ml and 130.5 ng/ml, respectively) (Figure 2b).
The mean MMF doses were decreased up to month 3
9 Discontinued study medication,
(14.8%) 
2 Adverse events 
6 Unsatisfactory therapeutic  effect
1 Subject withdrew consent 
5 Discontinued study
5 Subject withdrew consent 
Month12
56 Completed study phase (91.8%) 
52 Completed study medication
(85.2%) 
8 Discontinued study medication,
(13.1%) 
1 Adverse events
3 Unsatisfactory therapeutic  effect
4 Subject withdrew consent 
3 Discontinued study
3 Subject withdrew consent 
Month12
58 Completed study phase (95.1%) 








Figure 1 Patient disposition. MMF, mycophenolate mofetil.
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constant throughout the study. The mean ± standard
deviation dose of MMF at month 12 was 1.24 ± 0.530 g/
day. Mean everolimus and cyclosporine trough levels
and average daily doses of everolimus and MMF from
day 3 to month 12 are shown in Figure 2a,b and
Table 2.Efficacy
Primary efficacy endpoint
Composite efficacy failure event rates at month 12 were
identical in both groups (everolimus, 11.5% and MMF,
11.5%; Table 3). This treatment difference of 0.0% with the
upper limit of the 95% CI at 9.5% was lower than the pre-
defined non-inferiority margin of 13% confirming non-
inferiority of the everolimus group to the MMF group.
The Kaplan–Meier plot of the proportion of patients
free from composite efficacy failure over the 12-month
period confirmed similar efficacy for the everolimus and
MMF groups (see Additional file 1). There were four
patients in the everolimus group and two patients in the
MMF group who withdrew informed consent to partici-
pate in the study and for whom no further information
could be collected. These patients were accounted for
as lost to follow-up. There were two patients, one in
each group, who developed treated BPAR before discon-
tinuation of the study due to withdrawal of consent, and
hence they were not included in the loss to follow-up
category.Secondary efficacy endpoints
The main secondary efficacy endpoint (combined rate of
death, graft loss and LTFU) at month 12 was statistically
non-inferior for everolimus (8.2%) versus MMF (4.9%).
All of the events were due to LTFU with no cases of
graft loss or death (Table 3). Treated BPAR (based on
central biopsy readings) occurred in three (4.9%)
everolimus patients versus five (8.2%) MMF patients.
The majority of the treated BPARs were of Banff type
1A in the everolimus group (Table 3). These results were
confirmed based on local biopsy results with treated
BPAR occurring in four everolimus patients versus eight
MMF patients, with the majority of treated BPARs of
type IA or IB.
Safety
Renal function
Median eGFR at month 12 was 58.00 ml/minute/1.73 m2
with everolimus versus 55.25 ml/minute/1.73 m2 with
MMF (P = 0.063). For both treatment groups, the mean
and median eGFR gradually increased at a similar rate
during the first month after transplantation. The eGFR
levels were higher for the everolimus group through the
study but the treatment comparisons did not show any
statistically significant differences between the groups at
any time point (Table 4; see also Additional file 2). The
chronic kidney disease category was used as a guide to
evaluate the renal function. The proportion of patients
with month 12 eGFR ≥60 ml/minute/1.73 m2 was
higher with everolimus (46.4%) compared with MMF
Table 1 Summary of patient demographics and kidney transplantation background by treatment group
(intent-to-treat population)
Everolimus 1.5 mg (n = 61) MMF 2 g (n = 61)
Recipient characteristics
Age (years)
Mean ± standard deviation 42.5 ± 14.13 38.6 ± 11.36
Median (range) 42.0 (18 to 65) 36.0 (20 to 64)
Gender, n (%)
Male 46 (75.4) 37 (60.7)
Female 15 (24.6) 24 (39.3)
Body mass index (kg/m2)
Mean ± standard deviation 22.46 ± 4.03 21.79 ± 2.78
Median (range) 21.97 (15.5 to 37.5) 21.09 (16.0 to 27.6)
Primary disease leading to transplantation, n (%)
Glomerulonephritis/glomerular disease 16 (26.2) 9 (14.8)
Polycystic disease 3 (4.9) 3 (4.9)
Hypertension/nephrosclerosis 5 (8.2) 2 (3.3)
Diabetes mellitus 3 (4.9) 5 (8.2)
Interstitial nephritis 2 (3.3) 0 (0.0)
Obstructive disorder/reflux 6 (9.8) 3 (4.9)
IgA nephropathy 11 (18.0) 16 (26.2)
Unknown 8 (13.1) 16 (26.2)
Other 7 (11.5) 7 (11.5)
Current dialysis
None 12 (19.7) 8 (13.1)
Hemodialysis 42 (68.9) 48 (78.7)
Peritoneal dialysis 7 (11.5) 5 (8.2)
HLA mismatches
1 7 (11.5) 2 (3.3)
2 9 (14.8) 16 (26.2)
3 25 (41.0) 24 (39.3)
<3 16 (26.2) 18 (29.5)
≥3 45 (73.8) 43 (70.5)
Donor characteristics
Mean ± standard deviation age (years) 52.3 ± 8.99 55.2 ± 8.23
Deceased heart beating, n (%) 1 (1.6) 0 (0.0)
Deceased nonheart beating, n (%) 0 (0.0) 1 (1.6)
Living related, n (%) 36 (59.0) 43 (70.5)
Living unrelated, n (%) 24 (39.3) 17 (27.9)
HLA, human leukocyte antigen; IgA, immunoglobulin A; MMF, mycophenolate mofetil.
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(Table 4).
Adverse events and laboratory parameters
The overall incidence of AEs was comparable between
the treatment groups (Table 5). The proportion of
patients reporting any serious AEs was approximately10% higher for the MMF group (54.1%) versus the
everolimus group (44.3%) (risk ratio (RR) = 0.82 (95%
CI = 0.568, 1.178)). A higher proportion of the MMF
patients (26.2%) versus the everolimus (19.7%) patients
(RR =0.75 (95% CI = 0.388, 1.450)) experienced serious
infections, particularly serious CMV infections (18.0% vs.
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Figure 2 Mean everolimus and cyclosporine trough levels over time. (a) Mean everolimus trough levels over time for the everolimus 1.5 mg
group (safety population). At each visit the mean is shown and these are joined with horizontal lines. Whiskers are the 5th and 95th percentiles.
Target levels are displayed. (b) Mean cyclosporine trough levels for all treatment groups over time (safety population). At each visit the mean is
shown and these are joined with horizontal lines. Whiskers are the 5th and 95th percentiles. The target ranges are also displayed with solid lines
(lower limit) and broken lines (upper limit) for comparison with the values seen. MMF, mycophenolate mofetil.
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(3.3% vs. 0%, respectively).
The most common AEs were nasopharyngitis, hyper-
lipidemia, constipation, acne and hypertension, and the
majority of AEs (>85% in either group) were mild or
moderate in severity. AEs/infections leading to discon-
tinuation of the study drug occurred in 4.9% of the pa-
tients in the everolimus group (pyrexia, diffuse large B-cell
lymphoma and membranous glomerulonephritis) versus
1.6% in the MMF group (electrolyte imbalance and hirsut-
ism) (Table 5). A higher proportion of the MMF patients
(85.2%) versus the everolimus patients (24.6%) had AEs
requiring study drug dose adjustment/interruption(Table 5). This was mostly due to infections (52.5% in
MMF group vs. 13.1% in everolimus group). The incidence
of any infection was higher with MMF (93.4%) versus
everolimus (82.0%). Viral infections were more frequent in
the MMF group (80.3%) compared with the everolimus
group (27.9%) (RR = 0.35 (95% CI = 0.227, 0.529)), pre-
dominantly due to the higher rate of CMV (68.9% vs.
14.8%) (see Additional file 3). Only one patient in the
everolimus group (CMV-positive donor/CMV-negative
recipient) and six patients in the MMF group (three
CMV-positive donor/CMV-negative recipient and three
CMV-positive donor/CMV-positive recipient) received
CMV prophylaxis (see Additional file 4).
Table 2 Average daily doses of everolimus (mg/day) and
mycophenolate mofetil (g/day) by visit window (safety
population)
Everolimus 1.5 mg (n = 61) MMF (n = 61)
Visit window n Mean ± SD n Mean ± SD
Day 3 61 1.49 (0.0.048) 61 1.95 (0.194)
Day 7 60 1.70 (0.447) 61 1.88 (0.297)
Month 1 57 1.72 (0.539) 60 1.70 (0.475)
Month 3 55 1.70 (0.628) 58 1.33 (0.606)
Month 4 55 1.68 (0.611) 56 1.22 (0.595)
Month 6 55 1.65 (0.602) 55 1.28 (0.583)
Month 7 55 1.61 (0.610) 54 1.28 (0.570)
Month 9 54 1.68 (0.656) 54 1.25 (0.530)
Month 12 53 1.68 (0.705) 53 1.24 (0.530)
MMF, mycophenolate mofetil; SD, standard deviation.
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sporine nephrotoxicity was numerically higher in the
everolimus group (21.3%) than in the MMF group (9.8%)
(RR = 2.17 (95% CI = 0.881, 5.329)) (Table 5). Malignancies
were reported for two (3.3%) everolimus patients (one
patient with thyroid cancer and one patient with B-cell
lymphoma), whereas no malignancies were reported in
MMF patients. Wound healing events were reported for
24 (39.3%) everolimus patients and seven (11.5%) MMF
patients (RR = 3.43 (95% CI = 1.598, 7.357)). Wound
events were reported as serious AEs in three (4.9%)




Primary composite endpoint (at 12 months)a 7 (11.5)
Treated BPAR 3 (4.9)
Graft loss 0
Death 0
Loss to follow-upb 4 (6.6)
Secondary efficacy endpoints




Graft loss or death (month 12) 0
Graft loss, death or loss to follow-upc (month 12) 5 (8.2)
Data presented as n (%). aComposite of treated BPAR, graft loss, death, or loss to fo
are counted for the first event to occur. bA loss to follow-up in the primary endpoin
whose last day of contact was prior to day 316 (that is, prior to the month 12 visit w
not experience graft loss or death and whose last day of contact was prior to day 3
the composite efficacy endpoint, patients are recorded by the individual. dZ-test fo
for a one-sided test and should be compared with the 0.05 significance level. BPARthe wound healing events reported were mild (4.9% and
1.6%) to moderate (34.4% and 8.2%), with 0% and 1.6% of
events classified as severe in the everolimus and the MMF
groups, respectively. The most common wound healing
AE was lymphocele, which was reported for seven (11.5%)
everolimus patients and two (3.3%) MMF patients. Im-
paired healing was reported as an AE for six (9.8%)
everolimus patients and one (1.6%) MMF patient. Edema
occurred in 20 (32.8%) everolimus and eight MMF
patients (13.8%) (RR = 2.50 (95% CI = 1.194, 5.235)).
Proteinuria was reported as an AE in eight (13.1%)
everolimus patients and five (8.2%) MMF patients
(RR = 1.60 (95% CI = 0.555, 4.616)) (Table 5). The urinary
protein:creatinine ratio in the everolimus group was
slightly higher than in the MMF group throughout the
study (median at month 12 was 135.0 mg/g and 65.0 mg/g,
respectively). AEs generally associated with cyclosporine
were more frequently reported in the MMF group versus
the everolimus group (Table 5).
The mean and median systolic blood pressure and
diastolic blood pressure decreased from baseline for
both treatment groups (Table 6). Low neutrophil
counts (≤1,000/mm3) were observed for two (3.3%)
MMF patients. Hyperlipidemia was reported in 28
(45.9%) everolimus patients and 19 (31.1%) MMF
patients, and hypercholesterolemia was reported for
seven (11.5%) everolimus patients and six (9.8%) MMF
patients. High triglyceride levels (≥750 mg/dl) were
reported for one (1.6%) everolimus patient and high
total cholesterol levels (>350 mg/dl) for two (3.3%)-to-treat population)
MMF 2 g
(n = 61)
Comparison of everolimus vs. MMF









3 (4.9) 3.3% (10.6%), P = 0.015d
llow-up. For the individual components of the composite endpoint, patients
t is a patient who did not experience treated BPAR, graft loss, or death and
indow). cA loss to follow-up in the secondary endpoint is a patient who did
16 (that is, prior to the month 12 visit window). Note that for patients meeting
r everolimus – MMF ≥0.13 (non-inferiority test, P value for non-inferiority test is
, biopsy-proven acute rejection; MMF, mycophenolate mofetil.
Table 4 Renal function over 12 months (intent-to-treat population)
Visit
window
Everolimus 1.5 mg (n = 61) MMF 2 g (n = 61)
n Mean (SD) Median (range) P valuea vs. MMF n Mean (SD) Median (range)
eGFR (MDRD) (ml/minute/1.73 m2)
Baseline 61 12.17 (6.23) 10.70 (4.7 to 41.1) 0.420 61 14.00 (8.37) 11.00 (2.7 to 41.1)
Month 1 56 63.10 (25.441) 58.40 (18.5 to 123.3) 0.685 60 60.53 (19.339) 57.25 (23.5 to 14.7)
Month 12 56 62.09 (18.993) 58.00 (17.8 to 123.3) 0.063 58 56.34 (15.227) 55.25 (26.1 to 111.8)
<30 ≥30 to <60 ≥60 P value vs. MMF <30 ≥30 to <60 ≥60
Incidence rates of patients within renal function (eGFR MDRD) categories (n/month, %)
Month 1 5/56 (8.9) 26/56 (46.4) 25/56 (44.6) 0.541 1/60 (1.7) 31/60 (51.7) 28/60 (46.7)
Month 12 1/56 (1.8) 29/56 (51.8) 26/56 (46.4) 0.152 1/58 (1.7) 38/58 (65.5) 19/58 (32.8)
aWilcoxon rank-sum test comparing everolimus and MMF values. eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; MMF,
mycophenolate mofetil; SD, standard deviation.
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(Table 6).
Discussion
Results of this randomized study in Japanese de novo
kidney transplant patients indicate that everolimus with
reduced-exposure cyclosporine provides similar efficacy,
renal function and safety to MMF with standard-
exposure cyclosporine over the first 12 months post
transplant. These outcomes were achieved with ~52%
lower cyclosporine A trough concentration in the
everolimus treatment group versus the standard therapy
arm. The findings from this trial are comparable with
those reported in a large, predominantly Caucasian
population in the recent A2309 study [12].
There were no graft losses or deaths in either treatment
group, and rates of treated BPAR at 12 months were
notably low in both treatment arms (everolimus ~5%,
MMF ~8%). The low incidence of rejection partly reflects
the almost universal use of living donors in our cohort,
but slightly higher cyclosporine exposure than in the re-
cent A2309 study [12] may also have contributed. This
was balanced by a somewhat lower mean everolimus
trough concentration in the current trial. Recipient demo-
graphics were broadly similar in the two studies, although
donor age was slightly older in the current trial.
The key renal endpoint, eGFR (Modification of Diet in
Renal Disease) at month 12, did not differ significantly
between the two treatment groups (P = 0.063) but was
numerically higher in the everolimus cohort throughout
the trial. As might be expected in our living-donor
population, the mean eGFR was slightly higher than in
the larger A2309 study, but the pattern of difference
between treatment groups was comparable. The A2309
trial also showed the mean eGFR to be numerically
higher in the everolimus-treated patients at all time
points, but in that larger study population the between-
group difference became significant at months 1, 6, 7
and 9. In both trials, the proportion of patients withCKD stage ≥4 (that is, eGFR ≥60 ml/minute/1.73 m2) at
month 12 was higher in the everolimus group versus
the mycophenolic acid cohort, an encouraging finding
since renal function at 12 months post RTx is recog-
nized as predictive of long-term renal function [20]. No
everolimus-treated patient was reported to have severe
proteinuria in our population. The incidence of toxic
nephropathy was higher with everolimus versus MMF, a
difference that arose during the first 14 days after trans-
plantation. In that 2-week period, mean cyclosporine
trough levels in the everolimus group were no different
from those in the MMF group. Since everolimus is
known to potentiate cyclosporine-related nephrotoxicity
when cyclosporine exposure is high [7,9,15], the acute
nephrotoxicity that was observed may probably have
been largely caused by high cyclosporine exposure. Pre-
viously it has been reported that CNI-associated acute
nephrotoxicity early after transplant can be resolved with
dose reduction or interruption [21,22]. In this study with
subsequent reductions in cyclosporine exposure, the
eGFR for the everolimus group was higher than for the
MMF group at month 12 post transplantation, and no
difference in the rate of chronic nephrotoxicity was
reported between the two groups, highlighting the
importance of prompt and adequate CNI reduction in
the presence of everolimus.
The overall safety profile of everolimus was similar to
that seen in previous studies and no AEs were identified
that appeared to be specific to Japanese patients. Hyper-
lipidemia, insomnia, increased alkaline phosphatase, in-
creased luteinizing hormone and follicle stimulating
hormone, wound healing events and edema were more
frequent with everolimus, while the incidences of CMV
infection, nasopharyngitis, constipation and acne were
all higher with MMF. The incidence of serious AEs was
approximately 10% lower with everolimus compared
with MMF, with a notably lower rate of CMV reported
as serious infections among everolimus-treated patients
(1.6% vs. 18.0% of MMF-treated patients). A reduced
Table 5 Summary of adverse events over 12 months of treatment (safety population)
Everolimus 1.5 mg (n = 61) MMF 2 g (n = 61) Risk ratio (95% CI)
Any adverse event 61 (100) 61 (100) –
Serious adverse events 27 (44.3) 33 (54.1) 0.82 (0.568, 1.178)
Severe adverse events 7 (11.5) 8 (13.1) 0.88 (0.338, 2.263)
Adverse events leading to study drug discontinuationa 3 (4.9%) 1 (1.6%) 3.00 (0.321, 28.044)
Adverse events leading to study drug dose adjustment/interruption 15 (24.6) 52 (85.2) 0.29 (0.184, 0.453)
Most frequently reported adverse events and infections (≥20% of patients in any treatment group)b
Hyperlipidemia 28 (45.9) 19 (31.1) 1.47 (0.928, 2.339)
Nasopharyngitis 21 (34.4) 26 (42.6) 0.81 (0.514, 1.270)
Constipation 19 (31.1) 27 (44.3) 0.70 (0.441, 1.123)
Hypertension 19 (31.1) 18 (29.5) 1.06 (0.616, 1.808)
Insomnia 17 (27.9) 9 (14.8) 1.89 (0.914, 3.903)
Acne 15 (24.6) 22 (36.1) 0.68 (0.393, 1.184)
Headache 13 (21.3) 9 (14.8) 1.44 (0.667, 3.127)
Toxic nephropathy 13 (21.3) 6 (9.8) 2.17 (0.881, 5.329)
Blood alkaline phosphatase increased 13 (21.3) 7 (11.5) 1.86 (0.796, 4.334)
Pyrexia 13 (21.3) 12 (19.7) 1.08 (0.538, 2.181)
Iron deficiency anemia 12 (19.7) 13 (21.3) 0.92 (0.458, 1.858)
Diarrhea 11 (18.0) 15 (24.6) 0.73 (0.367, 1.466)
Increased blood creatinine 11 (18.0) 14 (23.0) 0.79 (0.388, 1.591)
Hyperuricemia 7 (11.5) 13 (21.3) 0.54 (0.231, 1.257)
Cytomegalovirus test positive 4 (6.6) 19 (31.1) 0.21 (0.076, 0.583)
Cytomegalovirus infection 3 (4.9) 21 (34.4) 0.14 (0.045, 0.454)
Other adverse events of interest
Cyclosporine-associated adverse events
Gingival hypertrophy 0 (0.0) 2 (3.3%) –
Gingival injury 0 (0.0) 1 (1.6%) –
Gingivitis 0 (0.0) 1 (1.6%) –
Tremor 4 (6.6%) 1 (1.6%) 4.00 (0.460, 34.767)
Hirsutism 1 (1.6%) 4 (6.6%) 0.25 (0.029, 2.173)
Hypertrichosis 2 (3.3%) 3 (4.9%) 0.67 (0.115, 3.850)
Everolimus-associated adverse events
Wound-healing eventc 24 (39.3) 7 (11.5) 3.43 (1.598, 7.357)
New-onset diabetesc 7 (11.5) 3 (4.9) 2.33 (0.633, 8.606)
Edema eventsc 20 (32.8) 8 (13.1) 2.50 (1.194, 5.235)
Stomatitis eventsc 14 (23.0) 10 (16.4) 1.40 (0.675, 2.904)
Blood luteinizing hormone increased 9 (14.8) 0 (0.0) –
Blood follicle stimulating hormone increased 8 (13.1) 1 (1.6) 8.00 (1.032, 62.040)
Proteinuria 8 (13.1) 5 (8.2) 1.60 (0.555, 4.616)
Investigator-reported severity
Mild 6 (9.8) 3 (4.9) 2.00 (0.524, 7.636)
Moderate 2 (3.3) 1 (1.6) 2.00 (0.186, 21.482)
Severe 0 (0.0) 1 (1.6) –
Data are presented as n (%). aFor patients with adverse events leading to discontinuation of study medication (recorded on the AE/Infection CRF page), the primary
discontinuation reason (recorded on the End of Treatment CRF page) is not necessarily ‘AE(s)’; rather, it may be ‘abnormal laboratory result(s)’ or ‘unsatisfactory
therapeutic effect’. bBy preferred term. cEvents were identified from a predefined list of adverse event preferred terms. MMF, mycophenolate mofetil.
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Table 6 Vital signs, hematological and biochemical
abnormalities over 12 months of treatment
(safety population)
Everolimus 1.5




≤90 mmHg or <75 mmHga 1 (1.6) 0 (0.0)
≥180 mmHg or >200 mmHgb 9 (14.8) 6 (9.8)
DBP (mmHg)
≤50 mmHg or <40 mmHg 4 (6.6) 0 (0.0)
≥105 mmHg or >115 mmHg 14 (23.0) 16 (26.2)
Hematology
Platelets, low: <50 k/mm3 0 (0.0) 1 (1.6)
Eosinophils, high: ≥12% 1 (1.6) 1 (1.6)
Hemoglobin, low: <7 g/dl 5 (8.2) 5 (8.2)
Lymphocytes, low: ≤1,000/mm3 48 (78.7) 56 (91.8)
Leukocytes
Low: ≤2.0 k/mm3 0 (0.0) 1/61(1.6)
High: ≥16 k/mm3 32 (52.5) 20 (32.8)
Neutrophils, low: ≤1,000/mm3 0 (0.0) 2 (3.3)
Lipids
Total cholesterol, high: ≥350 mg/dl 2 (3.3) 1 (1.6)
Triglycerides, high: ≥750 mg/dl 1 (1.6) 0 (0.0)
Cholesterol (total)/HDL ratio
High: ≥5 and ≤7 24 (39.3) 17 (27.9)
Very high: >7 5 (8.2) 3 (4.9)
Lipid modifying agents 42 (68.9) 24 (39.3)
Number of patients with normalized
cholesterol values after statin treatment
(n/month)
16/18 (88.9) 6/7 (85.7)
Number of patients with normalized
triglyceride values after statin treatment
9/12 (75) 3/4 (75)
Data presented as n (%). aDecrease from baseline ≥30 mmHg. bIncrease from
baseline ≥30 mmHg. DBP, diastolic blood pressure; HDL, high-density
lipoprotein; SBP, systolic blood pressure.
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with mycophenolic acid has been reported previously in
kidney transplantation [12,15], although the between-
group difference in CMV infection in the present study
was greater than in previous trials. This may have
resulted from more frequent CMV testing at Japanese
centers than is standard elsewhere. Reports in preclinical
studies state that mTOR inhibition may promote
differentiation of antiviral memory CD8 T cells [23,24],
upregulate proinflammatory cytokines, downregulate
anti-inflammatory cytokines, and boost major histo-
compatibility complex antigen presentation [25] effects
that would be expected to contribute to reduced viral
infection.
As a consequence of the low number of kidney trans-
plants performed each year in Japan, the study size wassmall, with relatively low statistical power. However, the
findings were remarkably similar to those observed in
the large A2309 study, which used a similar design. As
in A2309, the patients in this study were selected to be
of relatively low immunological risk, and in addition
were almost exclusively recipients of a living-donor graft.
The results may therefore not be generalizable to a
wider population. The core study was 12 months in
duration, which may not have been adequate to fully
examine the effect of an everolimus-based regimen on
renal function. An extension phase will provide data to
24 months. One should also note that although an open-
label design was mandatory because of the need to
adjust drug doses based on trough concentrations in
each patient, this does introduce the risk of reporting
bias, particularly for AEs.
In conclusion, as compared with other countries,
currently there are limited immunosuppressant options
available for RTx patients in Japan. This study in de novo
Japanese RTx patients demonstrated that everolimus
(targeting a C0 of 3 to 8 ng/ml) with minimized cyclospor-
ine exposure was non-inferior to MMF with standard-
exposure cyclosporine in preventing efficacy failure to 12
months post transplant. Renal function did not differ sig-
nificantly between the two groups, but was numerically
higher in the everolimus cohort throughout the study. No
safety concerns specific to Japanese patients were ob-
served. While relatively small, this trial benefits from a
multicenter, randomized design and is the first to validate
the results of the large A2309 study in a Japanese popula-
tion. The findings indicate that cyclosporine minimization
facilitated by everolimus is a viable immunosuppressive
regimen for Japanese recipients of a kidney transplant and
may also contribute to the long-term maintenance of good
graft function and patient survival.
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Additional file 1: Figure showing a Kaplan–Meier plot for the
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prophylaxis (safety population).
Abbreviations
AE: adverse event; BPAR: biopsy-proven acute rejection; C0: trough
concentration; CI: confidence interval; CMV: cytomegalovirus; CNI: calcineurin
inhibitors; ELISA: enzyme-linked immunosorbent assay; eGFR: estimated
glomerular filtration rate; LTFU: loss to follow-up; MMF: mycophenolate
Takahashi et al. Transplantation Research 2013, 2:14 Page 11 of 12
http://www.transplantationresearch.com/content/2/1/14mofetil; mTOR: mammalian target of rapamycin; RR: risk ratio; RTx: renal
transplant.
Competing interests
KT has links with the Novartis Speakers Bureau, and is an advisor. KU has
links with Novartis Speakers Bureau. NY has links with Novartis Speakers
Bureau. STa has links with Novartis Speakers Bureau. STe has links with
Novartis Speakers Bureau. RT is a Novartis employee. CC-A is a Novartis
employee. EK has links with Novartis Speakers Bureau for grant/research
support and as an advisor, and a special advisor for Otsuka Pharmaceutical
Factory Inc. (Naruto, Japan) from 2009.
Authors’ contributions
KT, KU, STa, NY, STe, and EK participated in the research design and
performance of the research. RT and CC-A performed the data analysis. All
authors read and approved the final manuscript.
Acknowledgements
This study was supported by Novartis Pharma K.K. Japan. The authors thank
Heike Schwende, PhD, Novartis Pharma AG Switzerland, for organizing the
development of the manuscript. They also thank Swati Machwe, PhD, and
Raghuraj Puthige, PhD, Novartis Healthcare Pvt. Ltd India for editorial
assistance.
Study sites and principal investigators: Kota Takahash (Niigata University
Medical and Dental Hospital), Noritoshi Amada (Sendai Shakaihoken
Hospital), Takashi Yagisawa (Jichi Medical University Hospital), Kenji Yuzawa
(National Hospital Organization Mito Medical Center), Takashi Kenmochi
(National Hospital Organization Chiba-East Hospital), Satoshi Teraoka (Tokyo
Women’s Medical University Hospital), Shohei Fuchinoue (Tokyo Women’s
Medical University Hospital), Kazunari Tanabe (Tokyo Women’s Medical
University Hospital), Atsushi Aikawa (Toho University Omori Medical Center),
Ken Nakagawa (Keio University Hospital), Kazunari Yoshida (Kitasato
University Hospital), Kazuharu Uchida (Nagoya Daini Red Cross Hospital),
Tsuneo Kinukawa (Shakai Hoken Chukyo Hospital), Kiyotaka Hoshinaga
(Fujita Health University Hospital), Shinichi Ito (Gifu University Hospital), Norio
Yoshimura (University Hospital, Kyoto Prefectural University of Medicine),
Shiro Takahara (Osaka University Hospital), Tatsuya Nakatani (Osaka City
University Hospital), Masato Fujisawa (Kobe University Hospital), Shinichirou
Tanaka (National Hospital Organization Okayama Medical Center), Hidehisa
Kitada (Kyushu University Hospital), and Shigeru Satoh (Akita University
Hospital).
Central biopsy committee members: Kunio Morozumi (Nagoya Daini Red
Cross Hospital), Yutaka Yamaguchi (Yamaguchi Pathology Laboratory), Michio
Nagata (University of Tsukuba), and Asami Takeda (Nagoya Daini Red Cross
Hospital).
Medical advisor: Eiji Kobayashi (Jichi Medical University).
Author details
1Division of Urology, Department of Regenerative and Transplant Medicine,
Graduate School of Medical and Dental Sciences, Niigata University, Niigata
951-8520, Japan. 2Department of Organ Transplant Surgery, Aichi Medical
University, Aichi 480-1195, Japan. 3Transplantation and Regenerative Surgery,
Graduate School of Medical Science, Kyoto Prefectural University of Medicine,
Kyoto 602-8566, Japan. 4Department of Advanced Technology for
Transplantation, Osaka University Graduate School of Medicine, Osaka
565-0871, Japan. 5Department of Transplant Surgery, International University
of Health and Welfare Atami Hospital, Shizuoka 413-0012, Japan. 6Novartis
Pharma K.K, Tokyo 106-8618, Japan. 7Novartis Pharma AG, Basel CH-4002,
Switzerland. 8Division of Development of Advanced Treatment, Center for
Development of Advanced Medical Technology, Jichi Medical University,
Tochigi 329-0498, Japan.
Received: 13 March 2013 Accepted: 18 June 2013
Published: 16 July 2013
References
1. The Japanese Society for Clinical Renal Transplantation: Annual progress
report from the Japanese renal transplant registry: number of renal
transplantations in 2008, part 2. ISYOKU 2009, 44:548.
2. Golshayan D, Pascual M: Minimization of calcineurin inhibitors to improve
long-term outcomes in kidney transplantation. Transpl Immunol 2008, 20:21.3. Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR: The
natural history of chronic allograft nephropathy. N Engl J Med 2003,
349:2326.
4. Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Chapman JR, Allen RD:
Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol
histology. Transplantation 2004, 78:557.
5. Schuler W, Sedrani R, Cottens S, Häberlin B, Schulz M, Schuurman HJ, Zenke
G, Zerwes HG, Schreier MH: SDZ RAD, a new rapamycin derivative:
pharmacological properties in vitro and in vivo. Transplantation 1997,
64:36.
6. Tedesco-Silva H Jr, Vitko S, Pascual J, Eris J, Magee JC, Whelchel J, Civati G,
Campbell S, Alves-Filho G, Bourbigot B, Garcia VD, Leone J, Esmeraldo R,
Rigotti P, Cambi V: Haas T; 2306 and 2307 Study Groups: 12-month safety
and efficacy of everolimus with reduced exposure cyclosporine in de
novo renal transplant recipients. Transpl Int 2007, 20:27.
7. Lorber MI, Mulgaonkar S, Butt KM, Elkhammas E, Mendez R, Rajagopalan PR,
Kahan B, Sollinger H, Li Y, Cretin N: Tedesco H; B251 Study Group:
Everolimus versus mycophenolate mofetil in the prevention of rejection
in de novo renal transplant recipients: a 3-year randomized, multicenter,
phase III study. Transplantation 2005, 80:244.
8. Vitko S, Tedesco H, Eris J, Pascual J, Whelchel J, Magee JC, Campbell S,
Civati G, Bourbigot B, Alves Filho G, Leone J, Garcia VD, Rigotti P, Esmeraldo
R, Cambi V, Haas T, Jappe A, Bernhardt P, Geissler J, Cretin N: Everolimus
with optimized cyclosporine dosing in renal transplant recipients:
6-month safety and efficacy results of two randomized studies.
Am J Transplant 2004, 4:626.
9. Vitko S, Margreiter R, Weimar W, Dantal J, Kuypers D, Winkler M, Øyen O,
Viljoen HG, Filiptsev P, Sadek S, Li Y, Cretin N, Budde K: RAD B201 Study
Group: Three-year efficacy and safety results from a study of everolimus
versus mycophenolate mofetil in de novo renal transplant patients.
Am J Transplant 2005, 5:2521.
10. Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T: Everolimus and
reduced-exposure cyclosporine in de novo renal-transplant recipients:
a three-year phase II, randomized, multicenter, open-label study.
Transplantation 2004, 78:1332.
11. Chan L, Greenstein S, Hardy MA, Hartmann E, Bunnapradist S, Cibrik D, Shaw
LM, Munir L, Ulbricht B, Cooper M: CRADUS09 Study Group: Multicenter,
randomized study of the use of everolimus with tacrolimus after renal
transplantation demonstrates its effectiveness. Transplantation 2008,
85:821.
12. Tedesco-Silva H Jr, Cibrik D, Johnston T, Lackova E, Mange K, Panis C, Walker
R, Wang Z, Zibari G, Kim YS: Everolimus plus reduced-exposure CsA versus
mycophenolic acid plus standard-exposure CsA in renal-transplant
recipients. Am J Transplant 2010, 10:1401.
13. Dantal J, Francois Berthoux F, Moal M-C, Rostaing L, Legendre C, Genin R,
Toupance O, Moulin B, Merville P, Rerolle JP, Bayle F, Westeel PF, Glotz D,
Kossari N, Lefrançois N, Charpentier B, Quéré S, Di Giambattista F, Cassuto E:
RAD A2420 Study Group: Efficacy and safety of de novo or early
everolimus with low cyclosporine in deceased-donor kidney transplant
recipients at specified risk of delayed graft function: 12-month results of
a randomized, multicenter trial. Transpl Int 2010, 23:1084.
14. Salvadori M, Scolari MP, Bertoni E, Citterio F, Rigotti P, Cossu M, Dal Canton
A, Tisone G, Albertazzi A, Pisani F, Gubbiotti G, Piredda G, Busnach G,
Sparacino V, Goepel V, Messa P, Berloco P, Montanaro D, Veroux P, Federico
S, Bartezaghi M, Corbetta G, Ponticelli C: Everolimus with very low-
exposure cyclosporine a in de novo kidney transplantation: a
multicenter, randomized, controlled trial. Transplantation 2009, 88:1194.
15. Vitko S, Margreiter R, Weimar W, Dantal J, Viljoen HG, Li Y, Jappe A, Cretin N:
RAD B201 Study Group: Everolimus (Certican) 12-month safety and
efficacy versus mycophenolate mofetil in de novo renal transplant
recipients. Transplantation 2004, 78:1532.
16. Japanese package insert of Certican tablet: [http://www.info.pmda.go.jp/
downfiles/ph/PDF/300242_3999022F1028_1_08.pdf]
17. Basic Principles on Global Clinical Trials: Pharmaceuticals and Medical Devices
Agency (PMDA Notification No. 0928010). [http://www.pmda.go.jp/english/
service/pdf/notifications/PFSB-ELD-0928010.pdf]
18. Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM,
Cecka MJ, Cosyns JP, Demetris AJ, Fishbein MC, Fogo A, Furness P, Gibson
IW, Glotz D, Hayry P, Hunsickern L, Kashgarian M, Kerman R, Magil AJ,
Montgomery R, Morozumi K, Nickeleit V, Randhawa P, Regele H, Seron D,
Seshan S, Sund S, Trpkov K: Antibody-mediated rejection criteria – an
Takahashi et al. Transplantation Research 2013, 2:14 Page 12 of 12
http://www.transplantationresearch.com/content/2/1/14addition to the Banff 97 classification of renal allograft rejection.
Am J Transplant 2003, 3:708.
19. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic
kidney disease and decreased kidney function in the adult US
population: Third National Health and Nutrition Examination Survey.
Am J Kidney Dis 2003, 41:1.
20. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson
CP: Post-transplant renal function in the first year predicts long-term
kidney transplant survival. Kidney Int 2002, 62:311.
21. Morozumi K, Thiel G, Albert FW, Banfi G, Gudat F, Mihatsch MJ: Studies on
morphological outcome of cyclosporine-associated arteriolopathy after
discontinuation of cyclosporine in renal allografts. Clin Nephrol 1992,
38:1–8.
22. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD:
Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol
histology. Transplantation 2004, 78:557–565.
23. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, Larsen
CP, Ahmed R: mTOR regulates memory CD8 T-cell differentiation.
Nature 2009, 460:108.
24. Turner AP, Shaffer VO, Araki K, Martens C, Turner PL, Gangappa S, Ford ML,
Ahmed R, Kirk AD, Larsen CP: Sirolimus enhances the magnitude and
quality of viral-specific CD8(+) T-cell responses to vaccinia virus
vaccination in rhesus macaques. Am J Transplant 2011, 11:613.
25. Saemann MD, Haidinger M, Hecking M, Hörl WH, Weichhart T: The
multifunctional role of mTOR in innate immunity: implications for
transplant immunity. Am J Transplant 2009, 9:2655.
doi:10.1186/2047-1440-2-14
Cite this article as: Takahashi et al.: Efficacy and safety of concentration-
controlled everolimus with reduced-dose cyclosporine in Japanese de
novo renal transplant patients: 12-month results. Transplantation Research
2013 2:14.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
